ENTX Profile
Entera Bio Ltd. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing orally delivered large molecule therapeutics to address unmet medical needs. The company’s innovative approach focuses on creating effective oral delivery systems for complex drugs, which traditionally require injection. Entera Bio's lead product candidates include EB612, which is currently in Phase II clinical trials for the treatment of hypoparathyroidism, and EB613, which has completed Phase II clinical trials for osteoporosis and is also undergoing Phase I trials for non-union fractures.
EB612 is designed to provide a non-invasive treatment option for patients with hypoparathyroidism, a rare endocrine disorder that affects calcium regulation in the body. EB613, on the other hand, aims to offer improved treatment for osteoporosis, a condition characterized by weakened bones, and is being investigated for its potential in addressing non-union fractures, where bones fail to heal properly after a fracture.
Entera Bio has also established a research collaboration and license agreement with Amgen Inc., a global biopharmaceutical leader. This partnership focuses on the development and discovery of clinical candidates for inflammatory diseases and other serious medical conditions, leveraging Amgen’s expertise and resources to advance Entera Bio’s therapeutic innovations.
Founded in 2009 and headquartered in Jerusalem, Israel, Entera Bio Ltd. is at the forefront of developing cutting-edge oral drug delivery technologies. The company’s commitment to overcoming the limitations of traditional drug delivery methods highlights its role in advancing patient care through novel therapeutic solutions.
|
